PRLD Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 May 2024 @ 11:46):

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients...

Stats
Today's Volume	12 904.00
Average Volume	68 903.00
Market Cap	250.75M
EPS	$0 ( 2024-03-20 )
Next earnings date	( $-0.470 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.830
ATR14	$0.0470 (1.27%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-04	Huang Jane	Sell	9 375	Restricted Stock Unit
2024-04-04	Huang Jane	Buy	9 375	Common Stock
2024-04-04	Huang Jane	Sell	3 347	Common Stock
2024-03-01	Lim Bryant David	Buy	150 000	Employee Stock Option (right to buy)
2024-03-01	Scherle Peggy	Buy	150 000	Employee Stock Option (right to buy)

INSIDER POWER
99.32
Last 98 transactions
Buy: 26 942 964 \| Sell: 353 466

Prelude Therapeutics Correlation

10 Most Positive Correlations
XOS	0.828

10 Most Negative Correlations
BNIXU	-0.842

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Prelude Therapeutics Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-1.17M (0.00 %)
EPS:	$-2.02

FY	2023
Revenue:	$0
Gross Profit:	$-1.17M (0.00 %)
EPS:	$-2.02

FY	2022
Revenue:	$0
Gross Profit:	$-3.04M (0.00 %)
EPS:	$-2.27

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-2.43

Financial Reports:

No articles found.

Prelude Therapeutics

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; PRT3645, a brain penetrant molecule that potently and selectively targets CDK4/6; and PRT-K4 that is in preclinical stage for solid tumors. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.